<p>根据 MarketBeat 的报道，Adagene Inc. 赞助的 ADR（NASDAQ:ADAG - 获取免费报告）目前被五家覆盖该股票的券商给予了 “买入” 的平均推荐。一位分析师对该股票给予了卖出评级，两位分析师给予了买入评级，另外两位分析师则对该公司给予了强烈买入评级。在过去一年中，更新了对该股票覆盖的券商的平均一年目标价为 8.00 美元。</p>
<p>多位股票分析师对 ADAG 股票发表了评论。华尔街 Zen 在 3 月 21 日的报告中将 Adagene 的股票评级上调至 “持有”。Guggenheim 在 4 月 6 日的报告中将 Adagene 的目标价从 9.00 美元提升至 10.00 美元，并给予该股票 “买入” 评级。最后，Weiss Ratings 在 1 月 21 日的报告中重申了对 Adagene 股票的 “卖出（d-）” 评级。</p>
<p><strong>查看我们对 Adagene 的最新分析</strong></p>
<h2>对 Adagene 的对冲基金看法</h2>
<p>大型投资者最近增持或减持了该公司的股份。Fifth Lane Capital LP 在第四季度将其在 Adagene 的持股增加了 427.3%。Fifth Lane Capital LP 现在拥有 145,000 股该公司的股票，价值 274,000 美元，此前在上个季度又收购了 117,500 股。Exome Asset Management LLC 在第四季度收购了价值约 2,004,000 美元的 Adagene 新头寸。SmartHarvest Portfolios LLC 在第四季度收购了价值约 73,000 美元的 Adagene 新头寸。Citadel Advisors LLC 在第三季度收购了价值约 80,000 美元的 Adagene 新头寸。最后，Gordian Capital Singapore Pte Ltd 在第三季度将其在 Adagene 的持股增加了 101.4%。Gordian Capital Singapore Pte Ltd 现在拥有 48,342 股该公司的股票，价值 96,000 美元，此前在上个季度又收购了 24,342 股。目前，9.51% 的股票由机构投资者持有。</p>
<h2>Adagene 价格表现</h2>
<p>NASDAQ:ADAG 周三开盘价为 3.81 美元。Adagene 的 1 年最低价为 1.30 美元，1 年最高价为 4.75 美元。该公司的 50 日移动平均价为 3.48 美元，200 日移动平均价为 2.47 美元。该公司的速动比率为 3.07，流动比率为 3.07，债务与股本比率为 0.03。</p>
<p>Adagene（NASDAQ:ADAG - 获取免费报告）最近于 2 月 14 日发布了季度财报。该公司报告季度每股收益为（0.04）美元。该季度的收入为 384 万美元。研究分析师预计 Adagene 在当前财年将发布-0.6 的每股收益。</p>
<h2>Adagene 公司简介</h2>
<p>（获取免费报告）</p>
<p>Adagene Inc.总部位于中国苏州，是一家临床阶段的生物制药公司，专注于抗体基础治疗药物的发现和开发，主要用于癌症和免疫相关疾病。公司成立于 2017 年，利用其专有的免疫组学技术平台挖掘人类抗体库，并设计新型单特异性和双特异性抗体。Adagene 的产品线包括多个处于临床前和早期临床开发阶段的候选药物，重点针对肿瘤微环境和调节免疫检查点，以增强抗肿瘤疗效。</p>
<p>Adagene 研发工作的核心是其 Bihanc™抗体平台，该平台结合了组合噬菌体展示、基于结构的设计和人工智能，以优化结合亲和力、特异性和开发性。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票，而不是 Adagene</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QURBRw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QURBRw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Adagene 吗？</h2>
<p>在你考虑 Adagene 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Adagene 并不在名单上。</p>
<p>虽然 Adagene 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

天演药业

<p>Adagene Inc.（纳斯达克代码：ADAG）获得了五家券商的平均推荐评级为 “买入”，其中包括一个卖出评级、两个买入评级和两个强力买入评级。平均一年目标价为 8.00 美元。最近的机构投资包括 Fifth Lane Capital 将其持股比例提高了 427.3%。Adagene 的股票开盘价为 3.81 美元，过去一年股价范围为 1.30 美元至 4.75 美元。该公司专注于针对癌症和免疫相关疾病的抗体治疗，利用其自主研发的 Bihanc™抗体平台</p>

<p>Shares of Adagene Inc. Sponsored ADR (NASDAQ:ADAG - Get Free Report) have been given an average recommendation of &#34;Buy&#34; by the five brokerages that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, two have given a buy rating and two have issued a strong buy rating on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $8.00.</p>
<div class="lb-trans"><p>根据 MarketBeat 的报道，Adagene Inc. 赞助的 ADR（NASDAQ:ADAG - 获取免费报告）目前被五家覆盖该股票的券商给予了 “买入” 的平均推荐。一位分析师对该股票给予了卖出评级，两位分析师给予了买入评级，另外两位分析师则对该公司给予了强烈买入评级。在过去一年中，更新了对该股票覆盖的券商的平均一年目标价为 8.00 美元。</p>
</div><p>A number of equities analysts have commented on ADAG shares. Wall Street Zen upgraded shares of Adagene to a &#34;hold&#34; rating in a report on Saturday, March 21st. Guggenheim boosted their target price on shares of Adagene from $9.00 to $10.00 and gave the stock a &#34;buy&#34; rating in a report on Monday, April 6th. Finally, Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Adagene in a report on Wednesday, January 21st.</p>
<div class="lb-trans"><p>多位股票分析师对 ADAG 股票发表了评论。华尔街 Zen 在 3 月 21 日的报告中将 Adagene 的股票评级上调至 “持有”。Guggenheim 在 4 月 6 日的报告中将 Adagene 的目标价从 9.00 美元提升至 10.00 美元，并给予该股票 “买入” 评级。最后，Weiss Ratings 在 1 月 21 日的报告中重申了对 Adagene 股票的 “卖出（d-）” 评级。</p>
</div><p><strong>Check Out Our Latest Analysis on Adagene</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Adagene 的最新分析</strong></p>
</div><h2>Hedge Funds Weigh In On Adagene</h2>
<div class="lb-trans"><h2>对 Adagene 的对冲基金看法</h2>
</div><p>Large investors have recently added to or reduced their stakes in the company. Fifth Lane Capital LP increased its holdings in shares of Adagene by 427.3% during the fourth quarter. Fifth Lane Capital LP now owns 145,000 shares of the company's stock valued at $274,000 after acquiring an additional 117,500 shares in the last quarter. Exome Asset Management LLC acquired a new position in shares of Adagene during the fourth quarter valued at about $2,004,000. SmartHarvest Portfolios LLC acquired a new position in shares of Adagene during the fourth quarter valued at about $73,000. Citadel Advisors LLC acquired a new position in shares of Adagene during the third quarter valued at about $80,000. Finally, Gordian Capital Singapore Pte Ltd increased its holdings in shares of Adagene by 101.4% during the third quarter. Gordian Capital Singapore Pte Ltd now owns 48,342 shares of the company's stock valued at $96,000 after acquiring an additional 24,342 shares in the last quarter. 9.51% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>大型投资者最近增持或减持了该公司的股份。Fifth Lane Capital LP 在第四季度将其在 Adagene 的持股增加了 427.3%。Fifth Lane Capital LP 现在拥有 145,000 股该公司的股票，价值 274,000 美元，此前在上个季度又收购了 117,500 股。Exome Asset Management LLC 在第四季度收购了价值约 2,004,000 美元的 Adagene 新头寸。SmartHarvest Portfolios LLC 在第四季度收购了价值约 73,000 美元的 Adagene 新头寸。Citadel Advisors LLC 在第三季度收购了价值约 80,000 美元的 Adagene 新头寸。最后，Gordian Capital Singapore Pte Ltd 在第三季度将其在 Adagene 的持股增加了 101.4%。Gordian Capital Singapore Pte Ltd 现在拥有 48,342 股该公司的股票，价值 96,000 美元，此前在上个季度又收购了 24,342 股。目前，9.51% 的股票由机构投资者持有。</p>
</div><h2>Adagene Price Performance</h2>
<div class="lb-trans"><h2>Adagene 价格表现</h2>
</div><p>NASDAQ:ADAG opened at $3.81 on Wednesday. Adagene has a 1-year low of $1.30 and a 1-year high of $4.75. The company has a 50-day moving average of $3.48 and a 200 day moving average of $2.47. The company has a quick ratio of 3.07, a current ratio of 3.07 and a debt-to-equity ratio of 0.03.</p>
<div class="lb-trans"><p>NASDAQ:ADAG 周三开盘价为 3.81 美元。Adagene 的 1 年最低价为 1.30 美元，1 年最高价为 4.75 美元。该公司的 50 日移动平均价为 3.48 美元，200 日移动平均价为 2.47 美元。该公司的速动比率为 3.07，流动比率为 3.07，债务与股本比率为 0.03。</p>
</div><p>Adagene (NASDAQ:ADAG - Get Free Report) last released its quarterly earnings data on Saturday, February 14th. The company reported ($0.04) earnings per share for the quarter. The company had revenue of $3.84 million for the quarter. Research analysts anticipate that Adagene will post -0.6 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Adagene（NASDAQ:ADAG - 获取免费报告）最近于 2 月 14 日发布了季度财报。该公司报告季度每股收益为（0.04）美元。该季度的收入为 384 万美元。研究分析师预计 Adagene 在当前财年将发布-0.6 的每股收益。</p>
</div><h2>Adagene Company Profile</h2>
<div class="lb-trans"><h2>Adagene 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Adagene Inc, headquartered in Suzhou, China, is a clinical-stage biopharmaceutical company specializing in the discovery and development of antibody-based therapeutics for cancer and immune-related diseases. Founded in 2017, the company leverages its proprietary immunome technology platform to mine human antibody repertoires and engineer novel monospecific and bispecific antibodies. Adagene's pipeline includes multiple candidates in preclinical and early clinical development, with a focus on targeting tumor microenvironments and modulating immune checkpoints to enhance anti-tumor efficacy.</p>
<div class="lb-trans"><p>Adagene Inc.总部位于中国苏州，是一家临床阶段的生物制药公司，专注于抗体基础治疗药物的发现和开发，主要用于癌症和免疫相关疾病。公司成立于 2017 年，利用其专有的免疫组学技术平台挖掘人类抗体库，并设计新型单特异性和双特异性抗体。Adagene 的产品线包括多个处于临床前和早期临床开发阶段的候选药物，重点针对肿瘤微环境和调节免疫检查点，以增强抗肿瘤疗效。</p>
</div><p>At the core of Adagene's research and development efforts is its Bihanc™ antibody platform, which combines combinatorial phage display, structure-based design and artificial intelligence to optimize binding affinity, specificity and developability.</p>
<div class="lb-trans"><p>Adagene 研发工作的核心是其 Bihanc™抗体平台，该平台结合了组合噬菌体展示、基于结构的设计和人工智能，以优化结合亲和力、特异性和开发性。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Adagene</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Adagene</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QURBRw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=ADAG"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Adagene Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Adagene 吗？</h2>
</div><p>Before you consider Adagene, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Adagene 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adagene wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Adagene 并不在名单上。</p>
</div><p>While Adagene currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Adagene 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

天演药业公司赞助的美国存托凭证（纳斯达克代码：ADAG）被分析师给予 “买入” 的平均推荐